Maral Maral Nogayeva

Prof. Maral Maral Nogayeva


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
AMAliya Makasheva
Aliya Makasheva
LYLyudmila S. Yermukhanova
Lyudmila S. Yermukhanova
KKKhatimya Kudabayeva
Khatimya Kudabayeva
STSaule Tazhbenova
Saule Tazhbenova
MNMaral Maral Nogayeva
Maral Maral Nogayeva
Aliya ZhylkybekovaAliya Zhylkybekova
Aliya Zhylkybekova
Gestational diabetes mellitus (GDM) represents a significant medical complication during pregnancy, with a global prevalence ranging from 2% to 26% and increasing by over 30% in recent decades. Therefore, the aim of our study is to assess the trends and distribution of published studies, as well as the contributions of countries, institutions, journals, and authors to the development of primary care for pregnant women with gestational diabetes. In this bibliometric analysis, we examine the role of primary health care in GDM from 1991 to 2024. The data were sourced from Scopus and Web of Science, encompassing 276 articles from 150 sources and involving 1375 authors. The analysis reveals a steady increase in publications, with a 4.29% annual growth rate. This study identifies the USA and UK as leading countries in GDM research, and there are significant international collaborations, with the USA having 17 joint articles with other countries. The University of Eastern Finland, Ohio State University, and Harvard University are noted as the most prolific institutions, with 23, 17, and 16 articles, respectively. Additionally, the journal Diabetes Care published the highest number of articles, totaling 635. Prominent authors such as Bernstein J. and McCloskey L., with seven articles each, have made substantial contributions to the field. Our work highlights the need to pay special attention to primary care for gestational diabetes, as many negative consequences of the disease can be prevented at this stage. Innovative approaches to screening for GDM can significantly improve treatment outcomes and reduce health risks, which will have long-term positive effects both for individual patients and society as a whole.

4 November 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
KNKanat Nurgaliyev
Kanat Nurgaliyev
BIBakytsholpan Issayeva
Bakytsholpan Issayeva
NSNikolay Soroka
Nikolay Soroka
DDDina Dilmanova
Dina Dilmanova
SISamal Issayeva
Samal Issayeva
IKIndira Karibayeva
Indira Karibayeva
Background: Golimumab is an approved tumor necrosis factor inhibitor for the treatment of ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA). Although randomized controlled trials have demonstrated its efficacy, evidence regarding long-term treatment maintenance remains limited. This systematic review and meta-analysis evaluated the efficacy, safety, and durability of golimumab therapy in patients with AS and axSpA. Methods: This review was conducted according to PRISMA 2020 guidelines and prospectively registered in PROSPERO (CRD420251130466). PubMed, ScienceDirect, Scopus, and Google Scholar were searched from inception to January 2026. Randomized placebo-controlled trials of subcutaneous or intravenous golimumab were pooled using random-effects risk ratios (RRs) with Hartung–Knapp 95% confidence intervals (CIs), analyzing the approved dose in multi-arm trials; extension studies were synthesized separately as single-arm proportions. Primary outcomes were ASAS20, ASAS40, BASDAI50, and serious adverse events (SAEs). Risk of bias was assessed with RoB 2 (trials) and the NHLBI before–after tool (extensions), and certainty with GRADE. Results: Seven publications representing four independent trials (834 randomized patients) were included. At Weeks 14–16, golimumab increased ASAS20 (RR 2.22, 95% CI 1.51–3.27; high certainty), ASAS40 (RR 3.25, 95% CI 1.89–5.59; high certainty), and BASDAI50 responses (RR 2.82, 95% CI 1.39–5.71; moderate certainty), corresponding to approximately 300–350 additional responders per 1,000 patients treated. Effects favored golimumab in both radiographic AS and non-radiographic axSpA, with no statistically significant subgroup difference (ASAS20, p = 0.065). Evidence on SAEs was very imprecise (three trials, 14 events; RR 0.83, 95% CI 0.08–8.54; low certainty), and the risk of any adverse event was similar to placebo (RR 1.05, 95% CI 0.85–1.29). In uncontrolled extensions, 72% (95% CI 35%–92%) and 63% (95% CI 31%–86%) of patients originally randomized to golimumab had ASAS20 and ASAS40 responses at Weeks 52–104 (very low certainty). Conclusion: High- to moderate-certainty randomized evidence shows that golimumab substantially improves short-term signs and symptoms of AS and axSpA compared with placebo. Safety data are too sparse to exclude important differences in serious adverse events, and evidence on durability of response is of very low certainty. All included trials were industry-sponsored, and independent long-term comparative studies are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251130466 , PROSPERO CRD420251130466.

28 August 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
ABA.B. Bakytova
A.B. Bakytova
SDS.е. Dairabay
S.е. Dairabay
RUR.B. Utepova
R.B. Utepova
MNMaral Maral Nogayeva
Maral Maral Nogayeva
AMA.R. Medeulova
A.R. Medeulova
BNBayan Kadirovna Nurgaliyeva
Bayan Kadirovna Nurgaliyeva
Introduction. Hemorrhagic vasculitis (HV), or Schönlein–Henoch purpura, is a systemic vasculitis of small vessels, predominantly mediated by IgA. Although the disease occurs relatively frequently in childhood, its manifestation in elderly patients is much rarer and typically presents with a more severe and torpid course. In older patients, the condition is often accompanied by pronounced visceral complications, including abdominal and renal syndromes, which significantly worsen the prognosis and require special attention in both diagnosis and treatment. This article presents a clinical case of hemorrhagic vasculitis in a geriatric patient. The disease manifested with the classical triad of symptoms: cutaneous purpura, abdominal pain syndrome, and renal involvement. Objective. To describe a clinical case of hemorrhagic vasculitis in an 86-year-old patient with concomitant cutaneous, abdominal, and renal syndromes on the background of significant comorbidities. Materials and Methods. This article presents the clinical case of an 86-year-old patient, V., who was admitted to the rheumatology department of the City Rheumatology Center in Almaty with complaints of hemorrhagic rashes on the upper and lower extremities, marked weakness, abdominal pain syndrome, episodes of nausea and vomiting, and oliguria. A comprehensive clinical, laboratory, and instrumental examination was conducted, including complete blood count, biochemical blood tests, urine analysis (including the Nechiporenko test), coagulation profile, immunological studies, abdominal ultrasound, ECG, and echocardiography. The diagnosis was established based on the patient’s complaints, clinical presentation, laboratory and instrumental findings, and in accordance with the EULAR (2010) classification criteria for adults. Results. The patient presented with typical symptoms of cutaneous hemorrhagic syndrome (symmetrical bluish-purple rashes that did not blanch under pressure), abdominal manifestations (nausea, vomiting, pain in the periumbilical area), and signs of renal involvement (episodes of oliguria, leukocyturia, elevated creatinine and urea levels). Under treatment with glucocorticosteroids, immunosuppressive therapy, infusion, and symptomatic therapy, positive dynamics were observed, including a reduction in the severity of skin manifestations, improvement in abdominal and renal symptoms, better laboratory values, and stabilization of the general condition. However, the disease course remained torpid, with prolonged healing of skin lesions, high sensitivity to medication changes, and the need for continuous cardiological and gastroenterological supervision. Conclusion. Early diagnosis, timely assessment of organ involvement, appropriate use of immunosuppressive and glucocorticosteroid therapy, and careful monitoring of complications are crucial for achieving favorable outcomes. Введение. Геморрагический васкулит (ГВ), или пурпура Шёнлейна-Геноха, является системным васкулитом мелких сосудов, преимущественно IgA-опосредованным. Несмотря на относительно частое возникновение заболевания в детском возрасте, его манифестация у пациентов старческого возраста встречается значительно реже и характеризуется более тяжелым, торпидным течением. У пожилых пациентов заболевание часто сопровождается выраженными висцеральными осложнениями, включая абдоминальный и почечный синдромы, что существенно ухудшает прогноз и требует особого внимания в диагностике и лечении. В статье представлен клинический случай геморрагического васкулита у пациента старческого возраста. Заболевание манифестировало классической триадой симптомов: кожным пурпурным, абдоминальным болевым синдромами и поражением почек. Цель. Описать клинический случай геморрагического васкулита у пациента 86 лет с сочетанным кожным, абдоминальным и почечным синдромами на фоне выраженной коморбидности. Материалы и методы. В данной статье приведен клинический случай пациента В., 86 лет, поступивший в ревматологическое отделение ГРЦ г. Алматы с жалобами на геморрагические высыпания на коже верхних и нижних конечностей, выраженную слабость, абдоминальный болевой синдромы, эпизоды тошноты, рвоты, также олигурии. Пациенту проведена комплексная клинико-лабораторная и инструментальная диагностика, включающая общий и биохимический анализы крови, анализы мочи (в т.ч. по Нечипоренко), коагулограмму, иммунологические исследования, УЗИ органов брюшной полости, ЭКГ, ЭхоКГ. Диагноз установлен на основании жалоб, клинической картины, лабораторно-инструментальных исследований с учетом...